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Abstract
Background: Persistent pulmonary hypertension of the newborn (PPHN) is characterized by vasoconstriction and
pulmonary vascular remodeling. Remodeling is believed to be a response to physical or chemical stimuli including
pro-mitotic inflammatory mediators such as thromboxane. Our objective was to examine the effects of hypoxia and
thromboxane signaling ex vivo and in vitro on phenotype commitment, cell cycle entry, and proliferation of PPHN
and control neonatal pulmonary artery (PA) myocytes in tissue culture.
Methods: To examine concurrent effects of hypoxia and thromboxane on myocyte growth, serum-fed first-passage
newborn porcine PA myocytes were randomized into normoxic (21 % O2) or hypoxic (10 % O2) culture for 3 days,
with daily addition of thromboxane mimetic U46619 (10−9 to 10−5 M) or diluent. Cell survival was detected by MTT
assay. To determine the effect of chronic thromboxane exposure (versus whole serum) on activation of arterial
remodeling, PPHN was induced in newborn piglets by a 3-day hypoxic exposure (FiO2 0.10); controls were 3
day-old normoxic and day 0 piglets. Third-generation PA were segmented and cultured for 3 days in physiologic
buffer, Ham’s F-12 media (in the presence or absence of 10 % fetal calf serum), or media with 10−6 M U46619.
DNA synthesis was measured by 3H-thymidine uptake, protein synthesis by 3H-leucine uptake, and proliferation by
immunostaining for Ki67. Cell cycle entry was studied by laser scanning cytometry of nuclei in arterial tunica media
after propidium iodide staining. Phenotype commitment was determined by immunostaining tunica media for
myosin heavy chain and desmin, quantified by laser scanning cytometry.
Results: Contractile and synthetic myocyte subpopulations had differing responses to thromboxane challenge.
U46619 decreased proliferation of synthetic and contractile myocytes. PPHN arteries exhibited decreased protein
synthesis under all culture conditions. Serum-supplemented PA treated with U46619 had decreased G1/G0 phase
myocytes and an increase in S and G2/M. When serum-deprived, PPHN PA incubated with U46619 showed
arrested cell cycle entry (increased G0/G1, decreased S and G2/M) and increased abundance of contractile
phenotype markers.
Conclusions: We conclude that thromboxane does not initiate phenotypic dedifferentiation and proliferative
activation in PPHN PA. Exposure to thromboxane triggers cell cycle exit and myocyte commitment to
contractile phenotype.
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Background
Interruption of the normal course of postnatal pulmon-
ary circuit relaxation can trigger the respiratory failure
and hypoxemia syndrome known as persistent pulmon-
ary hypertension of the newborn (PPHN) [1]. PPHN is
characterized by vasoconstriction followed by pulmonary
arterial fibrosis [2]. The pathophysiology of PPHN in-
volves multiple pathways of injury, including altered
circulating agonist balance, endothelial dysfunction,
smooth muscle dysfunction, and phenotype changes [3].
Despite improvements in perinatal care, inflammation
due to direct lung injury or sepsis continues to contrib-
ute significantly to the disease burden of PPHN. Vaso-
constriction is predominant early in the course of
PPHN, but arterial structural remodeling and fibrosis
progressively and irreversibly increases pulmonary vas-
cular resistance [4]. This remodeling is initiated within
days of disease onset in response to a wide variety of
stimuli, physical (mechanical stretch or strain) or chem-
ical (hypoxia, vasoactive growth factors). That a third of
PPHN patients have partial or unsustained responses to
nitric oxide vasodilation [5] suggests rapid onset of re-
modeling or loss of contractile phenotype. Patients with
fixed anatomic narrowing of the pulmonary circulation
constitute the majority of non-responders in PPHN
therapeutic trials [6].
Cyclooxygenase pathway metabolites contribute to the
early pulmonary hypertensive response [7, 8]. Thromb-
oxane A2 is an inflammatory prostanoid that binds to G-
protein-coupled sarcolemmal thromboxane prostanoid
(TP) receptors, leading to increased intracellular Ca2+,
sensitization of the contractile apparatus to Ca2+, and
pulmonary vasoconstriction [9]. Meconium-induced
lung injury is acutely associated with inflammation
and thromboxane release [5]. Thromboxane also me-
diates septic pulmonary hypertension in the neonate
[8, 10]. Diminished cyclooxygenase-1 and prostacyclin
synthase activities cause a shift in production of
arachidonic acid metabolites toward an increased
thromboxane to prostacyclin ratio, causing development
of increased pulmonary arterial tone [11]. Thromboxane
underlies the early development of pulmonary arterial
constriction in chronic hypoxic pulmonary hypertension
in newborns [12] and hyperoxia-induced pulmonary
hypertension [13]. The inhibition of thromboxane re-
duces pulmonary hypertension induced by hypoxia [14].
Cyclooxygenase-2 gene knockout exacerbates pulmonary
hypertension in chronic hypoxia; this effect is reversed
by TP blockade, which attenuates hypoxia-induced
pulmonary vasoconstriction [15]. Hypoxia also sensi-
tizes the dose-response relationship of pulmonary
arteries to TP stimulation; exposure to chronic hyp-
oxia markedly increases TP-mediated pulmonary vaso-
constriction [16].
An etiologic role for thromboxane in vasodilator-
unresponsive PPHN is substantiated by clinical data.
Increased serum thromboxane is reported in primary and
secondary pulmonary hypertensions, and may correlate
with disease severity. An imbalance between thromboxane
and prostacyclin production is implicated in pulmonary
hypertension accompanying hypoxic respiratory failure,
and increases pulmonary vascular resistance [17]. Infants
with a primary diagnosis of meconium aspiration have a
strong correlation between high pulmonary arterial pres-
sures and serial plasma thromboxane metabolite levels
[18, 19]. Infants with PPHN and hypoxemic respiratory
failure have higher serum thromboxane to prostaglandin
E2 ratios, compared with normals [20]. In neonates with
hypoxic PPHN treated with extracorporeal membrane oxy-
genation (ECMO), thromboxane metabolites are elevated
in severe cases but decrease concurrently with pulmonary
artery pressure upon successful medical management,
reflecting progressive resolution of lung injury [21].
A rise in thromboxane is thus associated with worsen-
ing PPHN and falling thromboxane with its alleviation.
While these data strongly implicate thromboxane as a
driver of disease severity, the specific role of thromb-
oxane in arterial remodeling has been difficult to dis-
cern. The pulmonary arterial histology of PPHN features
muscular layer thickening in small pulmonary arteries
and distal extension of muscle to nonmuscularized arter-
ies [22], involving myocyte hypertrophy, hyperplasia, and
increased deposition of collagen and elastin [23]. It is ar-
guable that signaling pathways for pulmonary vasocon-
striction and proliferative activation, including those
mediated by inflammation and thromboxane, have sig-
nificant overlap [24].
In this study, to examine the effect of thromboxane on
the initiation of PPHN arterial remodeling, we combined
in vitro thromboxane challenge of hypoxic pulmonary
arterial smooth muscle with organ culture studies on
pulmonary vessels from PPHN and control animals. This
approach has been used elsewhere to study vascular cell
differentiation and signaling, while maintaining cell
contact and cell-matrix interactions in an intact three-
dimensional tissue environment [25, 26]. We hypothe-
sized that thromboxane promotes cell cycle entry of
synthetic phenotype myocytes in the pulmonary arterial




All animal protocols were cleared by the University of
Manitoba Committee on Animal Use, within the guide-
lines of the Canadian Council on Animal Care. To in-
duce hypoxic PPHN, newborn piglets from a pathogen-
free farm supplier (<24 h of life; n = 5) were housed in
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normobaric hypoxic (FiO2 0.10, by admixture of room
air with N2) for 72 h in a sealed thermoregulated isolette
with appropriate diurnal cycling. The chamber was
opened for no more than 1 h a day for feeding and
cleaning. The use of half-atmospheric O2 tension is well-
established to induce pulmonary hypertension [27], and
is extensively studied in our hands [28–30]. Controls in-
cluded age-matched normoxic piglets obtained at 3 days
of age (n = 5) and newborn piglets (<24 h, n = 5). At the
conclusion of environmental exposure, piglets were
killed by pentobarbital overdose and exsanguination.
Heart and lungs were removed en bloc and placed in
oxygenated cold (4 °C) Ca2+-free Krebs-Henseleit
physiological buffer containing (in mM) the following:
112.6 NaCl, 25 NaHCO3, 1.38 NaH2PO4, 4.7 KCl, 2.46
MgSO4∙7H2O, and 5.56 dextrose (pH 7.4).
Primary pulmonary artery myocyte culture
Newborn piglets (<24 h age, n = 4) were euthanized as
above for primary culture of pulmonary arterial myocytes.
Second- to sixth-generation pulmonary arteries were ob-
tained by microdissection into Ca2+-free Krebs-Henseleit
physiological buffer. Arteries were permitted to recover in
cold Hepes buffered saline (HBS) solution (in mM: 130
NaCl, 5 KCl, 1.2 MgCl2, 10 HEPES, and 10 glucose; pH
7.4) supplemented with an antibiotic-antimycotic mixture
and gentamicin then washed with Ca2+-reduced HBS
(20 μM CaCl2) and finely minced. Tissue was transferred
to digestion medium containing Ca+2-reduced HBS, type I
collagenase (1750 U/ml), dithiothreitol (1 mM), bovine
serum albumin (BSA, 2 mg/ml), and papain (9.5 U/ml) for
15 min at 37 °C with gentle agitation. Dispersed pul-
monary arterial smooth muscle cells were collected by
centrifugation at 1200 rpm for 5 min, washed in Ca+2-
free HBS, and resuspended in Ham’s F-12 medium
supplemented with L-glutamine, 10 % fetal calf serum,
1 % streptomycin, and 1 % penicillin. Cells were
seeded on 100-mm plates at density 1 × 105 cells/mm
and utilized at first passage.
Cell survival
Primary myocytes were passaged onto 96-well plates
then serum-deprived for 2 days (in Ham’s F-12 medium
with L-glutamate-penicillin-streptomycin and 1 % insulin-
transferrin-selenium) to synchronize in a contractile
phenotype or grown in serum-supplemented media (10 %
fetal calf serum) to maintain a synthetic phenotype.
Serum-starved or serum-supplemented plates were then
randomized to growth in normoxia (21 % O2, 5 %CO2) or
hypoxia (10 % O2, 5 % CO2) for 72 h. During this time,
cells were exposed to U46619 (thromboxane mimetic) at
graded concentrations (10−9–10−5 M) or diluent, in the
presence or absence of 10−6 M thromboxane antagonist
SQ29548. Smooth muscle monoculture was confirmed by
immunostaining for α-sm-actin; differentiation into con-
tractile phenotype was confirmed by immunostaining for
smooth muscle myosin heavy chain. Cell survival was de-
termined by MTT Assay Kit (Cayman Chemical). Briefly,
cells were incubated with 20 μl MTT reagent in 100 μl
culture media for 3 h at 37 °C, followed by reaction ter-
mination. The bioreduced reaction product was quantified
at 570 nm using a microplate reader. To identify any off-
target effects of U46619 stimulation on prostaglandin re-
uptake, PGE2 concentration was determined in condi-
tioned media of serum-deprived normoxic and hypoxic
myocytes incubated for 4 h with 10−6 M U46619 or buffer,
in the presence or absence of 10−6 M SQ29548 by ELISA
(Life Technologies).
3H-thymidine incorporation
First-passage serum-starved or serum-supplemented
myocytes on 12-well plates as described above were ran-
domized to growth in normoxia (21 % O2, 5 %CO2) or
hypoxia (10 % O2, 5 % CO2) for 72 h, in the presence or
absence of 10−6 M U46619. Culture media was then re-
moved and 1 μCi of 3H-thymidine (thymidine-[methyl-
3H] specific activity 6.7 Ci/mmol; unit size 250 μCi;
Perkin Elmer) in 1 ml fresh media was added to each
well for 4 h of incubation in room air (21 % O2). Cells
were washed several times with 9 % NaCl then fixed
with 1 ml ice-cold 5 % trichloroacetic acid for 30 min.
The resulting precipitate was solubilized in 1 M NaOH
at room temperature. Solubilized DNA was transferred
into scintillation vials, and 3H-thymidine uptake was
quantified by scintillation counting, expressed as dpm/
105 cells.
Ex vivo PA tissue culture
Strips (1 cm) of third intrapulmonary generation neo-
natal pulmonary arteries from PPHN and control piglets
(9–12 strips per animal) were gently dissected under
sterile conditions, denuded of endothelium and cut lon-
gitudinally into halves. The strips were randomized to be
placed in 1 ml of sterile physiologic buffer (Ca2+-free
Krebs-Henseleit), serum-supplemented culture medium
(Ham’s F-12 supplemented with L-glutamate, 10 % fetal
calf serum, 1 % streptomycin, and 1 % penicillin), or
serum-deprived culture medium (Ham’s F-12 with L-
glutamate-penicillin-streptomycin, and 1 % insulin-
transferrin-selenium) for 72 h. All organ cultures were
incubated at 37 °C in normoxic conditions; during
this time, half of the strips also received treatment
with 10−6 M U46619.
DNA and protein synthesis
At the conclusion of the 3-day incubation as above, pul-
monary artery organ cultures were exposed for 24 h to
3H-thymidine (thymidine-[methyl-3H] specific activity
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6.7 Ci/mmol; unit size 250 μCi; Perkin Elmer) or 3H leu-
cine (L-leucine [4,5-3H (N)], specific activity 40–60 Ci/
mmol; unit size 250 μCi; Perkin Elmer) at activities
1 μCi/ml, respectively, in fresh media or physiologic buf-
fer. Tissues were liberally washed with 9 % NaCl and
digested in 200 μl 2 M NaOH. Protein concentrations
of tissue homogenates were determined by Bradford
method, using bovine serum albumin as a standard.
Scintillation fluid was added to 100 μl tissue hom-
ogenate and radioactivity was measured in a liquid
scintillation counter, expressed as cpm/mg of protein.
Immunofluorescence studies
Following organ culture as described above for 72 h in
media with or without serum, and in the presence or ab-
sence of stable thromboxane mimetic U46619, pulmon-
ary artery segments were fixed in 4 % formaldehyde,
washed in PBS, embedded in OCT Compound (Tissue-
Tek), frozen slowly to prevent tissue fracture, and stored
at −80 °C until use. Sections were cut at 10-μm thick-
ness on a cryostat, air-dried and kept at −20 °C, and
then permeabilized in 0.5 % Triton X-100 for 15 min at
room temperature. Nonspecific antibody binding was
blocked with 10 % donkey serum in cyto-TBS (in nM: 20
Tris base, 154 NaCl, 2 EGTA, 2 MgCl2, pH 7.4) for
30 min at room temperature in a humidified chamber.
Sections were evaluated for Ki67 (nuclear marker of
proliferating cells) by immunostaining for Ki67 (diluted
1:50; BD Pharmingen) and α-actin (1:100; Sigma) followed
by incubation with FITC-conjugated donkey anti-rabbit
antibody and Cy3-conjugated donkey anti-mouse anti-
body. Slides were evaluated by epifluorescence microscopy
by an observer blinded to treatment group; results were
expressed as Ki67 positive nuclei/mm2. For evaluation of
myocyte contractile machinery, sections were incubated
overnight at 4 °C with anti-myosin heavy chain (1:100;
Sigma) and anti-desmin (1:100; Sigma). For examination
of apoptosis, sections were incubated with anti-cleaved
caspase-3 (1:200; Sigma) and anti-BAX (1:50; Santa Cruz
Biotechnology), followed by the same secondary anti-
bodies. Sections were mounted with antifade and staining
intensity quantified by laser scanning cytometry (LSC;
iCYS ™ Research Imaging Cytometer), using Olympus IX-
71 microscope at ×40 objective. Contouring and event
segmentation were adjusted for optimal fluorescence de-
tection, at standardized fluorescence integral and max-
imum pixel fluorescence, in six to eight equally sized
regions of interest per slide with minimal cell-free areas.
Results were expressed as integral intensity/mm2.
Cell cycle entry
Sections were briefly hydrated in 2× sodium chloride cit-
rate buffer (2× SSC; 0.3 M NaCl, 0.03 M Na citrate; pH
7.0) and then incubated in 100 μg/ml DNase-free RNAse
in 2× SSC (ribonuclease A; Sigma) for 20 min at 37 °C.
Following several rinses, tissues were incubated with
propidium iodide (PI; 1:3000 in 2× SSC; Molecular
Probes) at room temperature in the dark for 5 min. Sec-
tions were then mounted with antifade and visualized by
LSC at ×40 magnification, 488 nm excitation, and 565–
595 nm emission to capture PI staining of nuclear DNA
[31, 32]. Gating was adjusted and standardized for opti-
mal detection of fluorescence events; data expressed as
integral fluorescence/event/cell count was calculated as
percentage of cells in 2N and 4N DNA cell cycle phases.
Pyknotic nuclei were quantified from the scattergram as
highest intensity (max pixel) events.
Statistical analysis
Statistical analyses utilized ANOVA with post-test Bon-
ferroni correction for multiple comparisons; p < 0.05 was
considered statistically significant. Data was presented as
mean ± SEM.
Results
Effect of thromboxane exposure on pulmonary artery
myocyte survival and growth
The effects of hypoxia and U46619 on cell survival
were evaluated by MTT assay. First-passage pulmon-
ary artery myocytes were either serum-deprived for
2 days to synchronize in a contractile phenotype or
maintained serum-fed (synthetic phenotype). Then, all
groups were randomized to normoxic (21 % O2, 5 %
CO2) or hypoxic (10 % O2, 5 % CO2) culture condi-
tions for 72 h and simultaneously exposed to graded
concentrations (10−9 to 10−5 M) U46619 added daily
for 3 days. Cell survival was quantified by MTT
colorimetric assay. All plates studied were near 80 %
confluence. Smooth muscle phenotype was routinely
confirmed by immunostaining for smooth muscle α-
actin and myosin heavy chain (not shown; similar
phenotyping data published [30]). Cell survival was
greater in serum-fed (synthetic) hypoxic myocytes
than in normoxic myocytes; this effect was significant
upon growth in high concentrations of U46619
(Fig. 1a(i)). Route of action of high dose U46619 was
verified by sensitivity to TP blockade. In contractile
phenotype myocytes, cell survival was diminished dur-
ing hypoxia and after incubation in U46619 (Fig. 1b(i)).
For a single-point analysis of DNA synthesis, cells
were incubated with 1 mCu per well 3H-thymidine in
fresh media added for 4 h at the end of environmental
exposures. 3H-thymidine uptake (as dpm/105 cells)
was comparable in normoxic and hypoxic synthetic
phenotype myocytes. U46619 exposure decreased thy-
midine incorporation in normoxic and hypoxic syn-
thetic myocytes, to a level consistent with that of
contractile myocytes; suppression of DNA synthesis
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was greater in normoxic cells (Fig. 1a(ii)). Contractile
myocytes exhibited low thymidine incorporation com-
pared to the synthetic myocytes, and this decreased
further during hypoxia and concomitant U46619
(Fig. 1b(ii)). Off-target effects of U46619 on prosta-
cyclin transporter-mediated PGE2 reuptake were de-
termined in conditioned media (Fig. 2). Neither
U46619 nor concurrent TP blockade had any effect
on media PGE2 accumulation. PGE2 concentration
was also not altered by hypoxia.
Effect of thromboxane exposure during PPHN or control
pulmonary artery tissue culture on cell growth and
protein synthesis
Third-generation intrapulmonary arteries from newborn
(day 0), 3-day-old control or 3-day hypoxic (PPHN) pig-
lets were maintained in either aerated Krebs buffer, cul-
ture medium with 10 % fetal bovine serum, or culture
medium without serum, and randomized to a daily treat-
ment with 10−6 M U46619 or diluent for 3 days. To
evaluate DNA synthesis, 3H-thymidine was added to
Fig. 1 First-passage pulmonary artery myocytes on 96-well plates, allowed to adhere for 24 h, then serum-starved for 2 days to synchronize in
a contractile phenotype, or maintained serum-fed (synthetic phenotype), followed by normoxic (21 % O2, 5 % CO2) or hypoxic (10 % O2, 5 %
CO2) culture conditions for 72 h, with serial concentrations (10
−9 to 10−5 M) of the stable thromboxane mimetic U46619, or 10−6 M SQ29548
(SQ; thromboxane receptor antagonist) added daily for 3 days. Cell survival by MTT assay; single-point analysis of DNA synthesis by 3H-thymidine
uptake. a [i] Cell survival in synthetic phenotype normoxic and hypoxic myocytes; growth in the presence of SQ, SQ plus 10−5 M U46619, or serial
concentrations of U46619. [ii] 3H-thymidine incorporation in normoxic and hypoxic synthetic myocytes following exposure to U46619. b [i] Cell
survival in contractile phenotype myocytes during hypoxia, in SQ, SQ plus 10−5 M U46619, or increasing concentrations of U46619. [ii] 3H-thymidine
incorporation in normoxic and hypoxic contractile myocytes during hypoxia and concomitant U46619 (in all panels, *p < 0.01 and
**p < 0.001 compared to normoxic untreated control, #p < 0.01 compared to hypoxic untreated; §p < 0.05 compared to normoxic cells in
same treatment group)
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culture media in the final 24 h; to quantify protein
synthesis, 3H-leucine was added to media for 24 h.
DNA synthesis increased in PPHN arteries compared
to age-matched control arteries when cultured in
media with serum and after chronic exposure to
U46619 (*p < 0.05; Fig. 3a(i)). In serum-starved tis-
sues, DNA synthesis and active protein synthesis
were low under all conditions when compared to
serum-fed tissues, and further attenuated by U46619
exposure (Fig. 3b(i), b(ii)). Active protein synthesis
was decreased in PPHN arteries compared to 3-day-
old controls in all tissue culture conditions (*p < 0.05;
Fig. 3a(ii), b(ii)).
Effect of thromboxane exposure on cell cycle entry in
serum-fed PPHN or control pulmonary artery
The presence of U46619 in serum-fed tissues during
normoxia or hypoxia decreased the percentage of cells
in G1/G0 stage from approximately 80 to 55 % (*p <
0.01). Cells in S stage increased in the presence of
U46619 compared to media controls (*p < 0.01). Cells in
G2/M cells were of relatively low frequency, lowest in
tissues maintained in physiological buffer, increased in
media, and significantly increased after U46619 stimula-
tion (Fig. 4). This was substantiated by increased Ki67-
positive nuclei in PPHN arteries chronically exposed to
U46619, compared to age-matched control arteries ex-
posed to U46619.
Effect of thromboxane exposure on cell cycle entry in
serum-starved PPHN or control pulmonary artery
The percentage of G1/G0 stage cells in the media of
arteries cultured in buffer or in serum-free media
was similar. PPHN arteries had fewer cells in G2/M
phase, and when chronically exposed to U46619,
they also had fewer cells in S phase and an increased
percentage of cells in G0/G1 (Fig. 5). Minimal Ki-67
staining was seen in serum-deprived tissues (data
not shown).
Effect of thromboxane exposure on apoptosis in PPHN or
control pulmonary artery
Immunostaining for activated caspase 3, a final effector
of apoptosis (Fig. 6a), and BAX, a key pro-apoptotic pro-
tein (Fig. 6b), was analyzed by laser scanning cytometry
in cultured PPHN and control pulmonary arteries
chronically exposed to U46619 in the absence of serum
supplementation. Tissues cultured in media had similar
levels of apoptosis markers. Activation of caspase-3 and
BAX abundance increased in control pulmonary arteries
exposed to U46619, but this did not occur in PPHN
arteries.
Effect of thromboxane exposure on phenotype of PPHN
or control pulmonary artery
Immunostaining for contractile phenotype marker
myosin heavy chain (Fig. 7a) and desmin (Fig. 7b)
was quantified in PPHN and control pulmonary ar-
teries by laser scanning cytometry of frozen sections
following tissue culture in the absence of serum sup-
plementation and after chronic exposure to U46619.
Myosin heavy chain and desmin staining was slightly
decreased in PPHN arteries compared to controls
when cultured in media alone; but in the presence
of U46619, staining for these contractile phenotype
markers increased dramatically.
Discussion
In this study, we examined smooth muscle proliferative
responses engendered by hypoxia and thromboxane, two
potent drivers of neonatal PPHN, in a piglet model of
neonatal pulmonary hypertension. Based on in vitro
studies and ex vivo tissue culture of neonatal pulmonary
arteries, we conclude that contractile and synthetic
phenotype smooth muscle subpopulations in PPHN had
differing responses to a thromboxane challenge. Pul-
monary artery myocytes studied in a synthetic pheno-
type had slightly increased survival and proliferation
during hypoxia, but the presence of U46619 decreased
proliferation of synthetic myocytes to lower levels seen
in contractile myocytes. Contractile phenotype pulmon-
ary myocytes grown in hypoxia had slightly decreased
survival and proliferation compared to those in nor-
moxia, with further attenuation upon incubation with
U46619. Tissue culture indicated that PPHN arteries
exhibited decreased protein synthesis under all cul-
ture conditions (DNA synthesis increased in serum-
supplemented PPHN pulmonary arteries exposed to
U46619 but decreased in serum-deprived PPHN ar-
teries). In serum-supplemented arteries, independent
of disease phenotype, the percentage of cells in G1/
G0 phase decreased during tissue culture in the
presence of U46619, with an increase in cells in S
and G2/M phase. Among serum-deprived arteries,
Fig. 2 First-passage pulmonary arterial myocytes grown in normoxia
or hypoxia for 3 days (without change of media), and incubated with
10−6 M U46619 or diluent, with or without 10−6 M TP antagonist
SQ29548 for 4 hours. PGE2 measured in conditioned media by
ELISA (p = ns)
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PPHN arteries exhibited arrest of cell cycle progres-
sion following U46619 challenge, with an increase in
G0/G1 and a decrease in S and G2/M phases. PPHN
arteries incubated with U46619 also showed evidence
of increased contractile phenotype commitment of
smooth muscle.
We interpret these findings to mean that thromb-
oxane does not initiate the phenotypic dedifferenti-
ation and proliferative activation that are the hallmark
of pulmonary arterial fibrosis in PPHN; on the con-
trary, exposure to thromboxane triggers cell cycle exit
and possibly expansion of the contractile smooth
muscle phenotype population. This is particularly evi-
dent during arterial organ culture in the absence of
serum, which replicates the normal in vivo environ-
ment of the endothelium-protected arterial media.
It has long been understood that inflammatory media-
tors stimulate pathways favoring both muscle contraction
Fig. 3 Third-generation pulmonary artery strips from newborn (control D0), normoxic 3-day-old (control D3), and hypoxic 3-day-old piglets
(PPHN D3) cultured for 72 h in aerated media with or without 10 % fetal bovine serum (favoring expansion of synthetic or contractile phenotype,
respectively). Tissue culture in Krebs physiological buffer also studied as a baseline control. Tissue strips were randomized to daily addition of
thromboxane mimetic U46619 for 72 h. Tissue DNA synthesis was evaluated by 3H-thymidine incorporation and protein synthesis by incorporation of
3H-leucine. Labeled amino acid or nucleotide was added for the final 24 h; tissue uptake expressed is as dpm/mg protein. Protein contents for tissue
homogenates from all groups were obtained by Bradford method. a [i] DNA synthesis, [ii] active protein synthesis in PPHN PA cultured in media with
serum, and after chronic exposure to U46619. b In serum-deprived tissues, decreased DNA synthesis [i] and active protein synthesis [ii] especially
following U46619 exposure. Protein content was lower in homogenates of PPHN arteries in media and in U46619 (N = 5; *p < 0.05 compared to control
D3 in same treatment group; #p < 0.05 compared to PA from same animal model in media alone)
Postolow et al. Fibrogenesis & Tissue Repair  (2015) 8:20 Page 7 of 13
and proliferation. In addition to its vasoconstrictor role,
thromboxane is known to have mitogenic effects [33]. In-
creased endothelial production of thromboxane is associ-
ated with vasoconstriction as well as with smooth muscle
hypertrophy leading to vascular remodeling. Loss of endo-
thelial integrity also results in contact of serum prolifera-
tive mediators with underlying vascular tissue, causing
medial and adventitial hypertrophy [34]. Hypoxia may dis-
turb endothelial function by altering regulation of vascular
tone, increasing permeability and promoting release of
growth factors [35]. In this study, we isolated the role of
thromboxane by adding it to a monotypic smooth muscle
culture and to an organ culture of endothelium-denuded
pulmonary artery, thereby excluding other endothelial
growth factors. In this model, thromboxane did not prove
to be mitogenic, as it sustained smooth muscle contractile
phenotype commitment without promoting dedifferenti-
ation or proliferation. We also sought to identify indirect
action of U46619 on prostaglandin transporter activity, as
a U46619-mediated increase in media PGE2 or PGI2
Fig. 4 Third-generation pulmonary artery strips from newborn (control D0), normoxic 3-day-old (control D3), and hypoxic 3-day-old piglets (PPHN
D3) cultured for 72 h in aerated media with 10 % fetal bovine serum (favoring synthetic phenotype) with daily addition of thromboxane mimetic
U46619 or diluent for 72 h. Tissues also studied in Krebs physiological buffer as a baseline control. Nuclei stained with propidium iodide. Proportion of
nuclei in each cell cycle stage (quantified by laser scanning cytometry) was calculated as percent cells in 2N and 4N DNA phases and expressed as integral
fluorescence/event/cell count. Apoptosis quantified as percent pyknotic nuclei (low area high fluorescence). Mitotic nuclei in medial layer of control and
PPHN arteries quantified after exposure to U46619, as Ki67-positive nuclei/mm2 (in all panels, *p < 0.05 compared to control D3 in same treatment
group; #p < 0.05 compared to PA from same animal group in media alone)
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could theoretically influence any observed anti-
proliferative effects [36]. We observed no accumula-
tion of media PGE2 following the 72-h hypoxia or
U46619 challenge; we have previously reported the
same for PGI2 [37]. Others have also reported in-
sensitivity of PGE2 reuptake to U46619 [38]. We
therefore exclude this off-target action and focus on
the effect of TP activation.
Vascular remodeling denotes morphological changes
of the vessel wall in response to noxious stimuli indu-
cing reorganization of the vessel wall structure, luminal
narrowing, and circuit hypoperfusion. Clinical triggers
for adaptive remodeling include hemodynamic stress,
mechanical injury, inflammation, and hypoxia [39]. In
later pulmonary hypertension, the poor response to va-
sodilators may represent relative loss of the contractile
component, as the increase in vascular resistance is due
to mural fibrosis, structural narrowing, and obliteration
of small distal pulmonary arteries [40]. As the major
component of vascular media, smooth muscle is the
main effector of pulmonary arterial remodeling [41].
Subpopulations of pulmonary arterial myocytes with dif-
fering proliferative potentials in response to injury are
distinguishable early in life [42]. These populations are
distinct with respect to their state of differentiation, ex-
pression of smooth muscle markers, and proliferative re-
sponses to growth factors and hypoxia [43]. Based on
functional physiology, morphology, and immunohisto-
chemistry, at least four smooth muscle phenotypes are
reported in the pulmonary arterial media [4]. The ex-
tremes of the phenotype continuum are the fully con-
tractile muscle cell with few synthetic organelles and no
capability of proliferation, and the synthetic smooth
muscle phenotype that is migratory, secretory, and cap-
able of division but with little contractile machinery
[44]. Under non-disease conditions, the majority of myo-
cytes exist in a contractile phenotype but quiescent state,
and only vascular injury causing exposure to serum fac-
tors activates the altered gene expression necessary for
cumulative hypertrophy or hyperplasia [45]. Medial
myocytes can be activated from cell cycle arrest into a
synthetically active and proliferative phenotype [46].
Fig. 5 Third-generation pulmonary artery strips from newborn (control D0), normoxic 3-day-old (control D3), and hypoxic 3-day-old piglets (PPHN
D3) cultured for 72 h in aerated media without serum (synchronizing cells in contractile phenotype) with daily addition of thromboxane mimetic
U46619 or diluent for 72 h. Tissues studied in Krebs physiological buffer served as a baseline control. Nuclei were stained with propidium iodide.
Proportion of nuclei in each cell cycle stage (quantified by laser scanning cytometry) was calculated as percent cells in 2N and 4N DNA phases
and expressed as integral fluorescence/event/cell count. Apoptosis was quantified as percent pyknotic nuclei (low area, high intensity). Mitotic
nuclei in medial layer of control and PPHN arteries quantified after exposure to U46619, as Ki67-positive nuclei/ mm2 (in all panels, *p < 0.05 compared
to control D3 in same treatment group; #p < 0.05 compared to PA from same animal group in media alone)
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This involves complex regulation of entry into the cell
cycle, a series of tightly regulated steps that control
DNA synthesis and mitosis. The resting (contractile)
myocyte is maintained in a non-proliferative gap phase
(G0); the activated myocyte enters the G1 phase where
the necessary elements are assembled to permit entry
into the synthetic phase (S phase) of DNA replication.
Cells subsequently enter a second gap phase (G2) during
which proteins that are used in mitosis are synthesized
[47]. In our model, exposure of both PPHN and control
pulmonary arteries to serum during organ culture in-
duced cell cycle progression, and this was increased in
the presence of exogenous thromboxane; this models
the effect of loss of endothelial integrity. Ki67 staining of
mitotic cells was also increased in serum-fed PPHN ar-
teries. However, upon tissue culture in the absence of
serum (which models the undamaged vessel), cell cycle
entry was halted in PPHN arteries, DNA synthesis
decreased, and protein synthesis diminished relative to
age-matched controls. Also in the absence of serum,
addition of exogenous thromboxane attenuated cell cycle
commitment. Increased immunostaining for contractile
protein markers in PPHN vessels following thromboxane
stimulation indicates thromboxane did not signal for de-
differentiation of smooth muscle in the medial layer.
This goes against literature implicating thromboxane
[48] and thromboxane receptor expression [49] in
hypoxic pulmonary arterial remodeling and loss of dis-
tensibility, and in rapid cell cycle progression of myo-
cytes [50]. However, this finding was supported by data
from cultured myocytes pre-synchronized by serum
deprivation or supplementation in contractile or syn-
thetic phenotype. DNA synthesis was naturally greater
in synthetic myocytes than contractile; but the presence
of U46619 virtually halted synthetic myocyte thymidine
uptake. Contractile myocytes had low DNA synthesis
under hypoxic conditions, with a small further decrease
after U46619 incubation. Examining the balance of sur-
vival versus apoptosis, hypoxia and U46619 increased
synthetic myocyte survival and decreased contractile
myocyte survival. PPHN vessels had a decreased abun-
dance of apoptotic markers, and in the presence of
serum, greater DNA synthesis (albeit lower protein syn-
thesis) in tissue culture indicating mural myocytes could
be induced toward proliferation in the presence of the
correct stimuli; however, in the absence of serum,
thromboxane alone suppressed DNA synthesis in PPHN
vessels. We interpret this to indicate that thromboxane
is not the serum element responsible for smooth muscle
proliferative signaling. When the majority population of
the arterial wall is muscle resting in the contractile
phenotype, thromboxane appears to promote cell cycle
exit and differentiation, with its attendant decrease in
proliferation and DNA synthesis. Further explication can
Fig. 6 Immunostaining for apoptotic markers, active caspase 3 (a)
and BAX (b), was analyzed by laser scanning cytometry in frozen
sections of pulmonary artery from control and PPHN animals,
following chronic exposure to U46619 added daily for 72 h in
the absence of serum. Results expressed as integral intensity/
mm2 area (**p < 0.001 compared to control D3 in same
treatment group; #p < 0.01 compared to PA from same animal
group in media alone)
Fig. 7 Immunostaining for contractile protein markers, myosin heavy
chain (a) and desmin (b), was analyzed by laser scanning cytometry in
frozen sections of pulmonary artery from control and PPHN animals,
following chronic exposure to U46619 added daily for 72 h in tissue
culture in the absence of serum. Results expressed as integral intensity/
mm2 area (*p < 0.01 compared to age-matched control)
Postolow et al. Fibrogenesis & Tissue Repair  (2015) 8:20 Page 10 of 13
be derived from studies linking thromboxane-mediated
mitogenic signaling with required co-stimulation by
other growth factors including platelet-derived growth
factor [51], oxidized lipoproteins [52], or other vasopres-
sors [53] and prevention of thromboxane-mediated
proliferation by polyunsaturated fatty acids [54]. Thromb-
oxane in isolation may act mainly as a vasoconstrictor but
may require other concurrent stimulation to act as a
mitogen. In addition, two TP receptor affinity sub-
types are identified, the higher affinity site associated
with thromboxane-induced vasoconstriction and the
lower affinity site with smooth muscle proliferation
[55]; we speculate that exogenous U46619 could trig-
ger signaling via high-affinity TP for vasoconstriction,
without activation of synthetic myocytes.
The novelty of this study lies in the combination of in
vitro and ex vivo methods with an analysis of cell cycle
entry to determine the specific role of thromboxane (as
opposed to associated serum factors) in smooth muscle
proliferative signaling. There are limitations inherent in
the use of ex vivo organ culture to study the effect of
prolonged thromboxane stimulation on pulmonary ar-
terial signaling. However, vascular tissue culture has
been used to investigate DNA and protein synthesis
in many different vessel types [56–59], maintaining
tissue viability, contractility, and relaxation for up to
5 days [59, 60]. Serum deprivation of cultured vessel
strips induces maximal force responses, while sup-
plementation with serum promotes tissue growth
and DNA synthesis, with decreased capacity for
force generation [61]; this manipulation is similar to
the effects of in vitro serum deprivation or supple-
mentation of cultured myocytes. Organ culture
methods offer greater control of experimental condi-
tions than in vivo studies while maintaining the
three-dimensional cell environment and avoiding dis-
ruption of tissue integrity [62].
Conclusions
We conclude inflammation and hypoxia appear to influ-
ence myocyte proliferation in a cell type-specific man-
ner. Hypoxia is a potent stimulus of smooth muscle
proliferation and pulmonary arterial remodeling. How-
ever, the presence of thromboxane increases smooth
muscle commitment to a contractile phenotype—this
may worsen vasoconstriction in PPHN. Despite our ini-
tial hypothesis that elevated serum thromboxane pro-
motes pulmonary vascular fibrosis in PPHN, our data
provide new evidence that the primary driver of
pulmonary artery medial proliferation is hypoxia and
that co-stimulation with thromboxane is not additive.
Therapeutic strategies for PPHN targeting vascular re-
modeling may need to take into account the effects of
inflammation.
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